4
but not in BDL rats, in which the main mediator appeared to be an enhanced eNOS-dependent vasodilatation, which was not liver selective, as it was associated with decreased arterial pressure. The potential use of Terutroban for portal hypertension requires further investigation.
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INTRODUCTION
In cirrhotic livers, increased resistance to portal blood flow resulting from architectural alterations of the liver parenchyma as well as from increased hepatic vascular tone is the primary factor in the pathophysiology of portal hypertension (1, 2) . Increased hepatic vascular tone is partly due to an increased production of cyclooxygenase-1 (COX-1)-derived vasoconstrictive prostanoids, such as thromboxane (TXA 2 ) (3, 4) together with an insufficient intrahepatic availability of the vasodilator nitric oxide (NO) (5, 6) .
We have previously demonstrated that, in isolated perfused cirrhotic livers, the blockade of the TXA 2 /PGH 2 (TP) receptor with SQ29548 corrected the hyperresponse to methoxamine (3) and improved endothelial dysfunction (4) of the hepatic vascular bed. Moreover, sinusoidal endothelial cells (SEC) isolated from cirrhotic rats overexpress COX-1 (7) and thromboxane synthase (TXAS) (8) , which represent an important source of vasoconstrictor prostanoids, such as TXA 2 (9) . Importantly, COX inhibition not only reduces the exaggerated TXA 2 production of cirrhotic SEC but also restores, at least in part, its decreased NO bioavailability (8) .
TP receptor ligands include TXA 2 , PGH 2 and isoprostanes (10, 11) . TXA 2 acts through its G-protein-coupled receptor leading to vasoconstriction by activating the RhoA/Rho-kinase pathway, and by increasing calcium levels in hepatic stellate cells (HSC) (12) . Terutroban is an orally active, specific antagonist of the TP-receptor (13) that improves endothelial-dependent vasodilation (14) , reduces inflammation (15) , attenuates oxidative stress and exerts antifibrotic effects (16, 17) in different vascular disorders. In addition, Terutroban has been 6 shown to reduce RhoA/Rho-kinase-dependent signaling and restore NO bioavailability in endotelial cells (18, 19) .
The current study aimed at evaluating the long-term effects of the in vivo blockade of TP receptor with Terutroban in two experimental rat models of cirrhosis, carbon tetrachloride (CCl 4 ) and bile duct ligation (BDL).
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MATERIALS AND METHODS
Induction of cirrhosis by carbon tetrachloride (CCl 4 )
Male Wistar rats weighing 50 to 75g underwent inhalation exposure to CCl 4 three times a week as previously described (20) . A high yield of micronodular cirrhosis was obtained after approximately 12 to 15 weeks of CCl 4 inhalation.
When the cirrhotic rats developed ascites, administration of CCl 4 was stopped.
Induction of cirrhosis by bile duct ligation (BDL)
Secondary biliary cirrhosis was induced in male Sprague-Dawley rats (200 to 225 g) by BDL as previously described (21) .
Terutroban treatment
Cirrhotic rats were randomized to receive Terutroban (30mg/Kg; n= 13 in CCl 4 ; n=14 in BDL; kindly supplied by Servier, Courbevoie Cedex, France) or its vehicle (1% hydroxyethylcellulose; n=8 in CCl 4 ; n=16 in BDL; Sigma-Aldrich, Tres Cantos, Madrid, Spain), administered orally by gavage, once a day, for 2 weeks. Treatment started one week after development of ascitis and stopping 
In vivo hemodynamic studies
Cirrhotic rats were anesthetised with intraperitoneal ketamine hydrochloride (100 mg/Kg; Merial Laboratories, Barcelona, Spain) plus midazolam (5 mg/kg intraperitoneally; Laboratorios Reig Jofré, Barcelona, Spain). The femoral artery and the ileocolic vein were cannulated with PE-50 catheters to measure mean arterial pressure (MAP; mmHg) and portal pressure (PP; mmHg) respectively. Perivascular ultrasonic transit-time flow probes connected to a flow meter (Transonic Systems Inc., Ithaca, NY, USA) were placed around the portal vein, as close as possible to the liver to measure portal blood flow perfusing the liver (PBF; mL/min/g liver) and around the superior mesenteric artery, in BDL cirrhotic rats, to measure superior mesenteric artery blood flow (SMABF, mL/minute/100g body weight). Hepatic vascular resistance (HVR, mmHg/mL/min/g liver) was calculated as: PP/PBF and superior mesenteric artery resistance (SMAR, mmHg/mL/min/100g body weight) was calculated as (MAP-PP)/SMABF. Blood pressures and flows were registered on a multichannel computer-based recorder (PowerLab; AD Instruments, Colorado Springs, CO). The temperature of the animals was maintained at 37± 0.5°C.
Hemodynamic data were collected after a 20 min stabilization period.
Page 8 of 37
Hepatology
Efficacy of TP receptor blockade
To determine if Terutroban correctly blocked the TP receptor, in a subgroup of CCl 4 and BDL cirrhotic rats (n=3) treated with Terutroban (30mg/kg) or vehicle for 2 weeks, measurements of MAP and PP were performed before and after the intravenous infusion of 10 µg/Kg U46619 (24) . U46619 (9,11-dideoxy-9α,11α-methanoepoxy-prosta-5Z,13E-dien-1-oic acid; Cayman Chem. Co.) is a synthetic TXA 2 analogue that specifically activates the TP-receptor.
Evaluation of endothelial function
An additional group of cirrhotic rats were randomized to receive Terutroban (30 mg/Kg; n= 8 in CCl 4 ; n =8 in BDL) or vehicle (n= 9 in CCl 4 ; n =9 in BDL) for three days. Rats were anesthetized and livers were quickly isolated and perfused by a flow-controlled perfusion system as previously described (25) .
The perfused rat liver preparation was allowed to stabilize for 20 min before vasoactive substances were added. The intrahepatic microcirculation was preconstricted by adding the α1-adrenergic agonist methoxamine (Mtx; 10 -4 mol/L; Sigma) to the reservoir. After 5 min, concentration-response curves to cumulative doses of acetylcholine (Ach; 10 -7 , 10 -6 , and 10 -5 mol/L; Sigma) were evaluated. Responses to Ach were calculated as per cent change in portal perfusion pressure (26) . The gross appearance of the liver, stable perfusion pressure, bile production over 0.4 ul/min/g of liver and a stable buffer pH (7.4 ± 0.1) were monitored during this period. If any viability criteria were not satisfied, the experiment was discarded.
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Biochemical analysis
At the end of the in vivo hemodynamic study, serum samples from cirrhotic rats were collected by cardiac puncture to subsequently evaluate alanine aminotransferase (ALT), aspartate aminoransferase (AST), bilirubin and albumin, all by standard protocols.
Assesment of Rho-kinase activity
Hepatic samples were obtained as previously described (27 
Evaluation of NO pathway
Western blot analysis of eNOS-phosphorylation and eNOS total protein expression eNOS-phosphorylation (eNOS-P) and eNOS total expression were assessed in hepatic homogenates using a rabbit antiphosphorylated eNOS at Ser Quantitative densitometric values of proteins were normalized to GAPDH.
cGMP levels
Measurements of cGMP, a secondary marker of NO bioavailability, were performed in rat liver homogenates treated with Terutroban or vehicle by enzyme immunoassay (Cayman Chem. Co. Tallin, Estonia) as previously described (28) .
Evaluation of hepatic fibrosis
Quantification of hepatic fibrosis
Livers from cirrhotic rats were fixed in 10% formalin, embedded in paraffin, sectioned and stained with 0.1% Sirius red, photographed, and analyzed using a microscope equipped with a digital camera. Eight fields from each slide were randomly selected, and the red-stained area per total area was measured using 
Protein expression of α-smooth muscle actin (α-SMA)
Hepatic protein expression of α-SMA was determined by Western blot in hepatic samples using a mouse antibody against α-SMA (1:1000, SigmaAldrich).
Collagen I and TGF-β gene expression
Hepatic mRNA expression of Collagen I and TGF-β was analyzed by real-time PCR using predesigned gene expression assays obtained from Applied Biosystems (AB, Foster City, CA) according to the manufacturer's protocol and reported relative to endogenous control GAPDH. All PCR reactions were performed in duplicate and using nuclease-free water as no template control.
Analysis of TP receptor expression in HSC
To directly study the expression of TP receptor, hepatic stellate cells (HSC)
were isolated from control, CCl 4 -, sham operated and BDL-rats as previously described (29) . In the CCl 4 model, HSC were isolated one week after development of ascitis and in the BDL model two weeks after surgery (when Terutroban treatment was initiated in the in vivo studies). TP receptor protein expression was determined by Western Blot in hepatic samples using a mouse antibody against TP receptor (1:1000; Cayman Chem Co.).
Statistical analysis
Statistical analysis was performed with the SPSS 18.0 for Windows statistical package (IBM Corp., Armonk, NY). All results are expressed as mean ± SEM.
Comparisons between groups were performed with the Student t test for unpaired data or with Mann-Whitney test when assumptions of normality could not be verified. Differences were considered significant at a P value < 0.05.
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RESULTS
Efficacy of TP receptor blockade in CCl 4 and BDL cirrhotic rats
As expected, infusion of U46619 produced a significant increase in MAP (23 ± 13%) and PP (11 ± 5%) in CCl 4 -cirrhotic rats treated with vehicle ( Fig 1A and 1B, black bars). By contrast, in CCl 4 -cirrhotic rats treated with Terutroban, the increase of MAP (3 ± 5%) and PP (2 ± 3%) in response to TP agonist was markedly attenuated, indicating an effective blockade of the TP-receptor (Fig 1A and 1B, white bars). Terutroban produced a similar blockade of the TP-receptor in BDL-cirrhotic rats, as shown by the attenuation of the increase in MAP (5 ± 3% vs 18 ± 8% in vehicle) and in PP (3 ± 3% vs 12 ± 3% in vehicle) caused by U46619 (Fig 1D, 1E) .
TP receptor protein expression in CCl 4 and BDL cirrhotic rats
TP receptor expression was determined in HSC from control, CCl 4 - (Fig 1C) and BDL-cirrhotic rats (Fig.1F) . Both cirrhotic models exhibited a significantly higher TP receptor expression compared to control rats.
Effects of chronic treatment with Terutroban in CCl 4 -cirrhotic rats
TP receptor blockade lowers portal pressure in CCl 4 -cirrhotic rats
PP was significantly lower in CCl 4 -cirrhotic rats treated with Terutroban (11.9 ± 2.8 mmHg) as compared with vehicle-treated rats (14.5 ± 1.4 mmHg) (mean difference -17.9%; p=0.035). This reduction was not associated with a significant change in PBF reflecting a fall in HVR (7.9 ± 2.6 vs 10.3 ± 2.9 mmHg/ml/min/g in vehicle-treated rats) (mean decrease 25%; p=0.047). MAP was not significantly reduced by Terutroban (Fig 2) .
14
TP receptor blockade attenuates Rho-kinase activity in CCl 4 -cirrhotic rats
To further explore the intrahepatic molecular mechanisms behind TP receptor blockade, we evaluated moesin phosphorylation in hepatic samples, a marker of Rho kinase activity. TP receptor blockade with Terutroban reduced hepatic moesin phosphorylation indicating a reduction in Rho-kinase activity (Fig 3B) .
Since RhoA/Rho-kinase may modulate eNOS activity, we characterized eNOS expression and phosphorylation. However, Terutroban administration did not modify eNOS phosphorylation at Ser 1176 (Fig 3C) , total eNOS expression ( Fig   3D) or hepatic cGMP levels (18.3 ± 2.9 pmol/ml vs 19.2 ± 3.4 pmol/ml in vehicle-treated rats) (Fig 3E) .
TP receptor blockade attenuates hepatic fibrosis in CCl 4 -cirrhotic rats
As expected, CCl 4 -cirrhotic rats exhibited a marked distortion of the normal liver architecture, as identified by staining of liver sections with Sirius Red.
Terutroban treatment produced a significant reduction in hepatic fibrosis, measured by the percentage of fibrosis area on Sirius Red stained liver sections (13.7% ± 4 vs 20.8% ± 3 in vehicle-treated rats) (Fig 4A) . This was associated with a significant reduction in collagen I mRNA expression (Fig 4B) , a marked decrease in α-SMA protein expression, a surrogate marker of HSC activation (Fig 4C) , and decreased TGF-β mRNA levels ( Fig 4D) .
Effects of TP receptor blockade on liver function in CCl 4 -cirrhotic rats
There were no significant differences in transaminases or bilirubin between CCl 4 -cirrhotic rats treated with vehicle or Terutroban. However, albumin levels Page 14 of 37
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were significantly increased in Terutroban-treated rats. Liver, spleen and body weight were not different between groups (Table 1A) .
TP receptor blockade improves endothelial dysfunction in CCl 4 -cirrhotic rats
Improved vasorelaxation in response to Ach was observed in three days
Terutroban-treated rats in comparison to cirrhotic rats treated with vehicle, that exhibited the expected impaired vasodilatory response to Ach (endothelial dysfunction) (Fig 3A) . than those receiving vehicle. As SMABF was similar in both groups, Terutroban produced a significant reduction in splanchnic arteriolar resistance (Fig 5) . (Fig 6C) and increased total eNOS expression (Fig 6D) , together with increased hepatic cGMP levels (7.2 ± 2.7 pmol/ml vs 4.1 ± 2.5 pmol/ml in vehicle-treated rats; p <0.05) (Fig 6E) .
Effects of chronic treatment with Terutroban in BDL-cirrhotic rats
TP receptor blockade attenuates Rho-kinase activity and improves NO bioavailability in BDL-cirrhotic rats
TP receptor blockade does not attenuate hepatic fibrosis in BDL-cirrhotic rats
Contrary to CCl 4 -cirrhotic rats, Terutroban administration to BDL rats did not reduce liver fibrosis as evaluated by the percentage of Sirius staining (36.9% ± 3.7 vs 34.7% ± 7.5 in vehicle) (Fig 7A) , and did not significantly change α-SMA protein expression (Fig 7C) , Type I collagen (Fig 7B) or TGF-β mRNA levels ( Fig 7D) .
Effects of TP receptor blockade on liver function in BDL-cirrhotic rats
There were no significant differences in transaminases, bilirubin or albumin between BDL cirrhotic rats treated with vehicle or Terutroban. Liver, spleen and body weight were not different between groups (Table 1B) .
TP receptor blockade improves endothelial dysfunction in BDL-cirrhotic rats
Livers from cirrhotic rats treated with vehicle exhibited an impaired vasodilatory response to Ach. Terutroban treatment significantly improved vasorelaxation in response to Ach (Fig 6A) .
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DISCUSSION
An increase in the hepatic production of the vasoconstrictor prostanoid TXA 2 has been shown to increase hepatic resistance in cirrhotic livers, contributing to increased portal pressure (3, 20, (30) (31) (32) . Up to now, in vivo efforts to reduce this increased hepatic resistance by reducing TXA 2 levels have been based on treatments with non-selective COX inhibitors (32, 33) . However, the strategy to block TXA 2 production by non-selective COX inhibition is not acceptable in cirrhosis due to its demonstrated deleterious effects on sodium and water retention and renal function (34, 35) . There are no previous reports of the effects of TP-receptor blockade in vivo in cirrhotic animals. We hereby report the effects of Terutroban, a specific TP-receptor blocker, in cirrhotic rats.
Terutroban has been extensively used in clinical trials in vascular diseases and proved to be safe (14, 36, 37) . Effects of the infusion of the thromboxane (TXA 2 ) agonist, U46619, in mean arterial pressure (MAP) and portal pressure (PP) in CCl 4 - (Fig 1A, 1B) and BDLcirrhotic rats (Fig 1D, 1E) Fig 1C) and BDL (Fig 1F) compared to HSC from sham rats.
Data are presented as mean ± SEM (n=4 per group). * p<0.05 vs sham. showed a significant decrease in moesin phosphorylation at Thr 558 in
Terutroban-treated rats.
Representative Western blot and analysis of (C) P-eNOS and (D) eNOS in (Fig 1A, 1B) and BDL-cirrhotic rats (Fig 1D, 1E ) treated with Vehicle or Terutroban. Measurements were obtained at baseline and after an intravenous infusion of the TXA2 agonist. Data as presented as % of increment above baseline and are mean ± SEM (n=3 per group). *p<0.05 vs.
Vehicle. Representative Western Blot of TP expression in isolated hepatic stellate cells (HSC) from sham, CCl4-and BDL-cirrhotic rats. Densitometry quantification in arbitrary units (AU) showed a significant increase in TP receptor expression in HSC from CCl4 ( Fig 1C) and BDL (Fig 1F) 
